HUTCHMED (China) Limited (AIM:HCM)
203.72
-6.28 (-2.99%)
May 28, 2025, 1:48 PM GMT+1
HUTCHMED (China) Employees
HUTCHMED (China) had 1,811 employees as of December 31, 2024. The number of employees decreased by 177 or -8.90% compared to the previous year.
Employees
1,811
Change (1Y)
-177
Growth (1Y)
-8.90%
Revenue / Employee
277.96K GBP
Profits / Employee
16.64K GBP
Market Cap
1.80B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
Genus | 3,500 |
Oxford Nanopore Technologies | 1,382 |
HUTCHMED (China) News
- 5 days ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 7 days ago - AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer - Benzinga
- 4 weeks ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 - GlobeNewsWire
- 5 weeks ago - AIM Market Roundup: Catenai, Seeen, Hutchmed - The Armchair Trader
- 5 weeks ago - HUTCHMED Completes Enrollment for Phase II Trial of Savolitinib in Gastric Cancer | HCM stock news - GuruFocus
- 5 weeks ago - HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - GlobeNewsWire
- 6 weeks ago - Hutchmed weighs cancer drug’s supply-chain options amid US-China trade war - South China Morning Post
- 2 months ago - HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewsWire